Adagio Medical Holdings (ADGM) EBITDA Margin (2023 - 2024)
Adagio Medical Holdings (ADGM) reported EBITDA Margin of 2725.0% for Q3 2024, up 2896159.0% year-over-year from N/an in Q4 2023, and up 220.75% on a QoQ basis from 2256.69% in Q2 2024.
Adagio Medical Holdings (ADGM) has 2 years of EBITDA Margin data on file, last reported at 2725.0% in Q3 2024.
- Quarterly EBITDA Margin rose 2896159.0% year-over-year to 2725.0% in Q3 2024, while the trailing twelve-month figure through Dec 2025 was 19078.79% (changed N/A YoY) and the FY2024 annual result came in at 19985.87%, down 778554.0% from the prior year.
- EBITDA Margin advanced to 2725.0% in Q3 2024 per ADGM's latest filing, from 2256.69% in the prior quarter.
- Across five years, EBITDA Margin topped out at 2725.0% in Q3 2024 and bottomed at 30826.92% in Q1 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 16.24% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 28.97% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 14.52% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 21.42% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 10.04% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 19.94% |
| 10 | Adagio Medical Holdings | 16.86 Mn | 3.95 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 2,725.00% |
| Jun 30, 2024 | -2,256.69% |
| Mar 31, 2024 | -30,826.92% |
| Dec 31, 2023 | -11,065.38% |
| Sep 30, 2023 | -26,236.59% |